The CooperCOO +0.52%89 Return-on-Tangible-Equity is -10.80% as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.88 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 758 Medical Devices & Instruments companies, The Cooper ranks better than 61.35% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. The Cooper's annualized net income for the quarter that ended in Apr. 2026 was $-312 Mil. The Cooper's average shareholder tangible equity for the quarter that ended in Apr. 2026 was $2,886 Mil. Therefore, The Cooper's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was -10.80%.
The historical rank and industry rank for The Cooper's Return-on-Tangible-Equity or its related term are showing as below:
COO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.33 Med: 16.8 Max: 366.83
Current: 8.33
During the past 13 years, The Cooper's highest Return-on-Tangible-Equity was 366.83%. The lowest was 8.33%. And the median was 16.80%.
COO's Return-on-Tangible-Equity is ranked better than 61.35% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs COO: 8.33
The Cooper (NAS:COO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
The Cooper Return-on-Tangible-Equity Related Terms
The Cooper Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for The Cooper's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where The Cooper's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -10.80% mean?
The Cooper (COO) has a Return-on-Tangible-Equity of -10.80% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The Cooper and its competitors. Over the past decade, The Cooper's Return-on-Tangible-Equity has ranged from 8.33 to 366.83. According to the industry distribution chart, The Cooper ranks #293 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 38.7%.
Is The Cooper's Return-on-Tangible-Equity too high?
The Cooper's current Return-on-Tangible-Equity is -10.80%. Over the past 10 years, this metric has ranged from a low of 8.33 to a high of 366.83. Based on the distribution chart, The Cooper ranks #293 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Return-on-Tangible-Equity compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #293 out of 758 companies for Return-on-Tangible-Equity. This puts The Cooper in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Historically, The Cooper's own Return-on-Tangible-Equity has ranged from 8.33 to 366.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Return-on-Tangible-Equity is -10.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $71.39 — trading 29.2% below its estimated fair value. The current Return-on-Tangible-Equity is -10.80%. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For The Cooper (COO), the current Return-on-Tangible-Equity is -10.80% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.39 is trading 29.2% below its estimated GF Value™ of $100.88.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Return-on-Tangible-Equity: -10.80%
GF Value™: $100.88 vs. price of $71.39 (29.2% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
